title: Tumor-suppressive effects of miR-29c on gliomas.
abstract: Although miR-29c has been shown to be expressed less in various kinds of solid cancers, its expression pattern and tumor-suppressive effects in gliomas remain largely unknown. In this study, we detected miR-29c in 10 nontumoral brain tissues and 60 gliomas of various grades and found that its labeling indexes were significantly lower in gliomas (53.7% for the nontumoral brain tissues, and 18.9, 5.5, and 1.8% for the WHO grade I-II, grade III, and grade IV glioma groups, respectively). We then overexpressed miR-29c in the SNB19 glioblastoma cell line and found that it markedly downregulated the expression level of CDK6, and accordingly increased the percentage of the tumor cells in the G1 phase from 44.5 to 69.1% and decreased the colony formation efficiency from 81.1 to 51.5%. miR-29c overexpression also increased the percentage of apoptotic cells from 27.2 to 54.8%, and led to a more than 50% decrease in the migratory and invasive abilities of the tumor cells. Our study shows that miR-29c can effectively block the proliferation of glioblastoma cells by inducing G1 arrest, promote their apoptosis, and inhibit their migration and invasion. At least some of its tumor-suppressive effects are mediated by specifically downregulating the expression of CDK6. Therefore, miR-29c can be used as a tumor suppressor in the gene therapy of malignant gliomas.
authors.affiliation: Department of Neuropathology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Cuiyun
authors.initials: C
authors.lastname: Sun
authors.forename: Yaping
authors.initials: Y
authors.lastname: Yan
authors.forename: Lin
authors.initials: L
authors.lastname: Yu
authors.forename: Degang
authors.initials: D
authors.lastname: Cheng
authors.forename: Tongling
authors.initials: T
authors.lastname: An
authors.forename: Cuijuan
authors.initials: C
authors.lastname: Shi
authors.forename: Jinling
authors.initials: J
authors.lastname: Xu
authors.forename: Changjuan
authors.initials: C
authors.lastname: Wei
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Wen
authors.forename: Shujun
authors.initials: S
authors.lastname: Zhao
authors.forename: Huining
authors.initials: H
authors.lastname: Li
authors.forename: Huimin
authors.initials: H
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Xu
authors.forename: Shizhu
authors.initials: S
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D002648:Child; D020552:Comet Assay; D005260:Female; D005434:Flow Cytometry; D005910:Glioma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D035683:MicroRNAs / Q000032:analysis / Q000235:genetics*; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055815:Young Adult
chemical_list: C532045:MIRN29a microRNA, human; D035683:MicroRNAs